IFN-Gamma Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Interferon-gamma is a dimerized soluble cytokine and the only member of type II class of interferons. IFNγ plays a role in regulating the immune response of its target cell; in both innate and adaptive immunity, its expression is upregulated and downregulated by the cytokines. Activating cell signaling pathways can promote inflammation, antiviral antibacterial activity, cell proliferation, and differentiation. Dysregulated IFNγ expression is associated with several autoinflammatory and autoimmune diseases. IFNγ inhibitors act by binding and neutralizing IFNγ. Their specific interaction with IFNγ inhibits the interaction between interferon-gamma and its cognate receptor on T-cells, producing the neutralizing activity. IFNγ inhibitors treat haemophagocytic lymphohistiocytosis. SOBI, UNION Therapeutics, Amgen, Kiora Pharma, Hanmi Pharmaceutical, Shanghai Pharma, and AprilBio are major players in the IFNγ inhibitors market.

Key Market Developments:

  • In Jan 2023, UNION Therapeutics, Orismilast received Fast Track status from the US FDA for hidradenitis suppurativa.
  • In Mar 2023, AB2 Bio planned to submit a marketing authorization application for Tadekinig alfa.

Approved Drug Molecules and Brand Names for IFNγ Inhibitors:

  • Gamifant (Emapalumab-lzsg)

Drugs under the Pipeline for IFNγ Inhibitors:

  • Orismilast oral (LEO 32731)
  • Vidofludimus (IMU-838)
  • Tadekinig alfa (IL-18BP)
  • AMG 811
  • KIO-101
  • LAPS-IFNα (HM10660A)
  • 5-Hydroxytriptolide
  • APB-R3
  • EI-001
  • SFA-002
  • Orismilast topical (LEO 32731 topical)

Clinical Activity and Developments of IFNγ Inhibitors:

Currently, there are 12 drug products in the IFNγ inhibitors, including one approved drug product and the rest of them are in the clinical development phases.

  • In Jan 2023, UNION Therapeutics released top-line efficacy and safety data from phase-IIb clinical trials in plaque psoriasis for Orismilast.
  • In Feb 2023, Syneos Health and AprilBio planned a phase-I trial for adult-onset Still’s disease in Australia for APB-R3, an IFNγ inhibitor.

Molecule Name

Number of Studies

Orismilast oral (LEO 32731)

12

Vidofludimus (IMU-838)

12

Tadekinig alfa (IL-18BP)

5

AMG 811

4

KIO-101

3

LAPS-IFNα (HM10660A)

2

5-Hydroxytriptolide

1

APB-R3

1

EI-001

1

SFA-002

1

Orismilast topical (LEO 32731 topical)

1

Target Indication Analysis of IFN-Gamma Inhibitors

IFNγ inhibitor Emapalumab is indicated for the treatment of patients with primary hemophagocytic lymphohistiocytosis, is in phase-II/III for COVID 19 infections, and in phase-II for transplant rejection. Other IFNγ inhibitors are being investigated for conditions such as multiple sclerosis, Crohn’s disease, ulcerative colitis, immunological disorders, adult-onset Still’s disease, and others.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

Gamifant (Emapalumab-lzsg) approved IFN-Gamma inhibitors in the market.

SOBI, UNION Therapeutics, Amgen, Kiora Pharma, Hanmi Pharmaceutical, Shanghai Pharma, and AprilBio are some of the major players in the IFN-Gamma inhibitors market.

Major indications for IFN-Gamma inhibitor is haemophagocytic lymphohistiocytosis.

There are a total of 11 molecules in the clinical development phases for IFN-Gamma inhibitors.

Adjacent Markets